The use of palmitoylethanolamide in backpain has been reported by Lambert in 2002, but was already known in the scientific communicty before that date. Now we found clear proof of such knowledge.
In 2001 it was also already known how useful palmitoylethanolamide was in low back pain. Quote:
PEA, a putative endocannabinoid, demonstrates some cannabinoid properties but does not bind to recombinant human cannabinoid receptors. However, anti-inflammatory activity in rodents has lead to clinical trials in chronic back pain as the drug “Palmidrol”
Anita Holdcroft, Parind Patel. Cannabinoids and pain relief September 2001, Vol. 1, No. 1 , Pages 92-99 (doi:10.1586/14737220.127.116.11)